Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002849 · ClinicalTrials.gov registry record · Phase 2
S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 93
- Enrollment target
NCT00002849 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 93 participants.
The verdict
NCT00002849, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 93 participants
- Enrollment target
Study Summary
RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary systemic amyloidosis.
Interventions
- DRUG dexamethasone
- BIOLOGICAL recombinant interferon alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 1996-11 |
| Est. Completion | 2000-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002849
The ClinicalTrials.gov registry entry for NCT00002849 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dexamethasone is the first listed.
NCT00002849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002849 about?
NCT00002849 is a clinical study titled "S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis". RATIONALE: Chemotherapy plus interferon alfa may be effective for primary systemic amyloidosis. PURPOSE: Phase II trial to study the effectiveness of dexamethasone plus interferon alfa in treating patients who have primary systemic amyloidosis.
What is the current status of trial NCT00002849?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 93 participants. The study started on 1996-11. Estimated completion is 2000-07.
What interventions are being tested in trial NCT00002849?
The interventions under investigation include: dexamethasone (DRUG), recombinant interferon alfa (BIOLOGICAL).
Who is sponsoring clinical trial NCT00002849?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.